Skip to search formSkip to main contentSkip to account menu

GP2013

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

rituximab

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
115 Introduction of biosimilars (similar biological) as financial saving to our countries for rheumatic diseases
Background Biosimilars are innovative therapeutic drugs which offer a cheaper alternation for biological which used for… 
2019
2019
Safety and Immunogenicity of Rituximab Biosimilar GP2013 After Switch From Reference Rituximab in Patients With Active Rheumatoid Arthritis
Comparable clinical efficacy of the rituximab (RTX) biosimilar GP2013 and reference RTX has been established in blinded… 
Highly Cited
2017
Highly Cited
2017
Rituximab biosimilar and reference rituximab in patients with previously untreated advanced follicular lymphoma (ASSIST-FL): primary results from a confirmatory phase 3, double-blind, randomised…
2017
2017
Rytuksymab – pierwsze biopodobne przeciwciała monoklonalne w hematoonkologii
2017
2017
Comparison of Switching from the Originator Rituximab to the Biosimilar Rituximab GP2013 or Re-Treatment with the Originator Rituximab in Patients with Active Rheumatoid Arthritis: Safety and…
Highly Cited
2017
Highly Cited
2017
A randomised, double-blind trial to demonstrate bioequivalence of GP2013 and reference rituximab combined with methotrexate in patients with active rheumatoid arthritis
Objectives The aim of this report is to demonstrate pharmacokinetic (PK) and pharmacodynamic (PD) equivalence as well as similar… 
2016
2016
FRI0222 Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of Proposed Rituximab Biosimilar (GP2013) vs. EU-Approved Rituximab (RTX) in Patients with Rheumatoid Arthritis: Results from A…
Background GP2013 has been developed as a proposed biosimilar to originator rituximab (RTX), by Sandoz, a Novartis Company. The… 
2014
2014
Target-directed development and preclinical characterization of the proposed biosimilar rituximab GP2013
Abstract Biosimilar development involves a target-directed iterative process to ensure a similar product to the originator. Here… 
2013
2013
Physicochemical, functional, and pharmacologic comparability between the proposed biosimilar rituximab GP2013 and originator rituximab as the foundation for biosimilarity.
3075 Background: Development of a biosimilar involves extensive characterization of the originator product and a target-directed… 
2013
2013
Physicochemical and Functional Comparability Between the Proposed Biosimilar Rituximab GP2013 and Originator Rituximab
Regulatory approval for a biosimilar product is provided on the basis of its comparability to an originator product. A thorough… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)